about
Association of plasma Aß peptides with blood pressure in the elderlyAmong vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts.Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: the AIBL Active trialLongitudinal assessment of Aβ and cognition in aging and Alzheimer disease.Genetic algorithm with logistic regression for prediction of progression to Alzheimer's diseaseA conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's diseaseThe effects of a protein enriched diet with lean red meat combined with a multi-modal exercise program on muscle and cognitive health and function in older adults: study protocol for a randomised controlled trial.Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies.Increased risk of cognitive impairment in patients with diabetes is associated with metformin.Incidence of cerebral microbleeds in preclinical Alzheimer disease.Research and standardization in Alzheimer's trials: reaching international consensus.Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).Personal memory function in mild cognitive impairment and subjective memory complaints: results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing.Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS).Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease.Implementation of subjective cognitive decline criteria in research studies.A randomized controlled trial of physical activity with individual goal-setting and volunteer mentors to overcome sedentary lifestyle in older adults at risk of cognitive decline: the INDIGO trial protocol.Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative.Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study.Aβ amyloid, cognition, and APOE genotype in healthy older adults.Larger temporal volume in elderly with high versus low beta-amyloid deposition.Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults.Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.Health professionals' and students' perceptions of elder abuse.The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI.Decline in cognitive function over 18 months in healthy older adults with high amyloid-β.Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.Blood-based protein biomarkers for diagnosis of Alzheimer disease.Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease.Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease.Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study.Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease.Longitudinal cognitive decline in the AIBL cohort: The role of APOE ε4 status.Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.
P50
Q28740991-C6AF0979-6107-420C-A619-11F8F454A61CQ30697272-8B78C204-D4ED-4F40-8BC3-E237D5EF9D56Q33884978-6F1C44A0-AC0E-471C-827F-5077B981D1CDQ34332159-68CC16F2-07AD-4783-93FD-67CFAD02DBC8Q34439105-41F64537-4C1D-4D6E-B3E2-4BF18E2DD53EQ34606557-2A8E87C8-DDE4-426F-936E-FAEA16F0647FQ34913389-9BEFB529-D454-4FBD-899B-60A2A36C6741Q35049917-AD6066E5-ADE7-4146-95F6-2B13081E1A88Q35930203-0A929557-CDA1-4ABE-9E7F-DB05A3FD541CQ36197614-E1BFA5D9-6890-4687-951E-D1DEB783C4AFQ37193677-461A7641-14B4-481C-BE24-FDBA62F45A56Q37725923-99245AF9-AA3C-42D2-A1C7-C8C6F8412C87Q38069699-A8108F70-A416-4309-A5E2-74D6ED9F3851Q38164141-E1B1DEEA-B588-4269-ADA3-9145D53386EFQ38436892-71164E8B-7DDF-4ABE-B7B4-3F998EB19B9FQ39440721-3B32FB4D-04DD-4026-A60F-A3649B7DB751Q39880236-3C645BC7-8E45-41F7-8AE6-C4F1FAA5691EQ39976878-838998E8-D5B4-40D7-B2B7-8488AB3B3ED1Q40483941-14942949-15B6-4FD0-A2C4-4FD908B33986Q41109879-B9D489EF-3A57-4FA0-8A86-D62CF62F927FQ43062420-728E7BF3-AF6B-4967-9DA6-750EAA78D046Q43069467-2CC41A17-3624-4B85-9C0C-6CD70CAF1EB2Q43107490-820CF16C-4D92-4E1D-BFA5-44278DFFDEB5Q43639226-C032D2AD-C4F6-4042-A9CA-C99BA15245AAQ43727342-0CD4FDD5-84E7-4F85-B0EA-81E66016006BQ43965311-8B46217F-8F81-42F2-8AA8-F97C2F7CE946Q44746948-0351FADB-A132-4C6C-9C28-18C23F7C6B5CQ44901723-C44EECAA-11F6-45B1-8CB6-B63B0AF05B72Q45966831-3F04C986-2832-4138-83F0-CC1665797FC7Q45987495-574095D0-7A18-4BAD-9A88-D66EF5F34BD8Q46177687-56735421-4F48-4CC8-AC6F-FE0F3A6FFA9BQ46741013-09B7E6EA-52C2-4B44-B2C6-A46C7B7554A4Q47378944-DA4C987C-8764-429F-B925-C582A53FAF05Q47747776-B77AB536-1086-4266-B97E-C6F74B2DC996Q48723395-044C799E-9E14-4BB5-BBE0-4FD7A8884618Q48756217-8CEE4E79-9CA7-4A66-9FA6-5DB6C5D996BFQ48918091-BB5AB941-FBB4-4BF1-B37E-5F4D2262D90EQ49132706-1AB185E5-A238-4450-8EF3-D6825C7C6B57Q50581545-491FE22D-0D22-4BF7-8403-9210E052ACCAQ50657023-310A3F60-21E5-45BC-8DC5-0D2B33EE3578
P50
description
researcher ORCID ID = 0000-0001-9097-9037
@en
wetenschapper
@nl
name
Kathryn A Ellis
@ast
Kathryn A Ellis
@en
Kathryn A Ellis
@es
Kathryn A Ellis
@nl
type
label
Kathryn A Ellis
@ast
Kathryn A Ellis
@en
Kathryn A Ellis
@es
Kathryn A Ellis
@nl
prefLabel
Kathryn A Ellis
@ast
Kathryn A Ellis
@en
Kathryn A Ellis
@es
Kathryn A Ellis
@nl
P1153
8983389800
P21
P2456
P31
P496
0000-0001-9097-9037